Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 873

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 873
---
 total amount, $1,679 was included in G&A expense in the stock option expense table above for the year ended December 31, 2022. During the year ended December 31, 2021, total incremental stock compensation expense relating to modifications of stock options and time-based restricted stock units of the former CEO was $5,056, which was included in G&A expense. Of that total amount, $4,908 is included in G&A expense in the stock option compensation expense table above for the year ended December 31, 2021. 16. Income Taxes The Company’s benefit from income taxes is as follows:

| ​                         
 ​                         
 Current:                  | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | December 31, 
 2023         
 ​            | ​ | ​ | ​ | ​ 
 ​ | ​ 
 ​ | 2022 
 ​    | ​ | ​ | ​ | ​ 
 ​ | ​ 
 ​ | 2021 
 ​    | ​ | ​ | ​ | ​ 
 ​ 
 ​ |
|:--------------------------|:--|:--|:-------------|:--|:--|:--|:--|:--|:-----|:--|:--|:--|:--|:--|:-----|:--|:--|:--|:--|
| Federal                   | ​ | ​ | ​            | $ | — | ​ | ​ | ​ | ​    | $ | — | ​ | ​ | ​ | ​    | $ | — | ​ | ​ |
| State                     | ​ | ​ | ​            | ​ | — | ​ | ​ | ​ | ​    | ​ | — | ​ | ​ | ​ | ​    | ​ | — | ​ | ​ |
| ​                         | ​ | ​ | ​            | ​ | — | ​ | ​ | ​ | ​    | ​ | — | ​ | ​ | ​ | ​    | ​ | — | ​ | ​ |
| Deferred:                 | ​ | ​ | ​            | ​ | ​ | ​ | ​ | ​ | ​    | ​ | ​ | ​ | ​ | ​ | ​    | ​ | ​ | ​ | ​ |
| Federal                   | ​ | ​ | ​            | ​ | — | ​ | ​ | ​ | ​    | ​ | — | ​ | ​ | ​ | ​    | ​ | — | ​ | ​ |
| State                     | ​ | ​